Stuttgart - Delayed Quote EUR

Alnylam Pharmaceuticals Inc (DUL.SG)

229.80

+7.10

+(3.19%)

At close: May 2 at 9:26:29 PM GMT+2

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

Zacks 16 hours ago

ALNY

REGN
Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ...

Alnylam Pharmaceuticals Inc (ALNY) reports strong financial performance with significant growth in TTR franchise and strategic advancements in RNAi therapeutics.

GuruFocus.com yesterday

ALNY
Q1 2025 Alnylam Pharmaceuticals Inc Earnings Call

Q1 2025 Alnylam Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents yesterday

ALNY
Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks yesterday

ALNY
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 98.21% and 1.02%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks yesterday

ALNY
Alnylam: Q1 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Alnylam Pharmaceuticals Inc. ALNY) on Thursday reported a loss of $57.5 million in its first quarter.

Associated Press Finance yesterday

ALNY
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

CAMBRIDGE, Mass., May 01, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2025 and reviewed recent business highlights.

Business Wire yesterday

ALNY
BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations

BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.

Investor's Business Daily 2 days ago

PFE

BBIO

ALNY
Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Alnylam (ALNY) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks 3 days ago

ALNY
Alnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In Europe

Alnylam Pharmaceuticals (NasdaqGS:ALNY) experienced an 8% price increase over the past week, likely spurred by a positive opinion from the European Medicines Agency (EMA) regarding its RNAi therapeutic, vutrisiran, for treating wild-type or hereditary transthyretin amyloidosis in adult patients. This regulatory milestone possibly provided support against broader market declines, with the Dow Jones, S&P 500, and Nasdaq Composite all witnessing losses after a four-day winning streak. Despite...

Simply Wall St. 4 days ago

ALNY
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 4 days ago

ALNY

AXSM
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

CAMBRIDGE, Mass., April 28, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of its RNAi therapeutic vutrisiran for the treatment of wild type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). ATTR-CM is a debilitating, rapidly p

Business Wire 4 days ago

ALNY
Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 8 days ago

ALNY
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

CAMBRIDGE, Mass., April 17, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May 1, 2025, before the U.S. financial markets open.

Business Wire 15 days ago

ALNY
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

We recently published a list of 10 Best Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against other best growth stocks to buy according to billionaires. Can the Stock Market Have a Big Rebound? The stock market has been […]

Insider Monkey 18 days ago

ALNY
High Growth Tech Stocks In US With Potential For Expansion

The United States market is currently experiencing a mixed performance with major indexes such as the Dow Jones and S&P 500 showing modest gains, while the tech-heavy Nasdaq Composite has seen slight declines amid fluctuating trade policies and tariff exemptions. In this dynamic environment, identifying high growth tech stocks with potential for expansion requires careful consideration of factors such as innovation, market adaptability, and resilience to external economic pressures.

Simply Wall St. 18 days ago

ALNY

ASND

NTRA
How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Political pressure and persistently high interest rates have some wondering if the industry’s model is broken.

The Wall Street Journal 21 days ago

ALNY

GILD

LLY
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 22 days ago

ALNY

IMNM
Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy

President Trump’s newly announced tariff policy has done more than just push the stock markets deeper into correction territory — the sudden panic on Wall Street has increased worries about a full-blown recession hitting in the near future. According to USA Today, several big banks are putting the chance of a recession at 40% or higher. Only time will tell if we dip into recession. For now, worried investors are seeking ‘recession-proof’ stocks to shore up their portfolios. The biopharma team at

TipRanks 22 days ago

ALNY

AXSM
Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires?

We recently published a list of 10 Best Long Term Growth Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against other best long term growth stocks to buy according to billionaires. As per Barclays, the US administration announced numerous executive […]

Insider Monkey 24 days ago

ALNY

Performance Overview

Return	DUL.SG	S&P 500 (^GSPC)
YTD	+1.50%	-3.31%
1-Year	+65.44%	+12.29%
3-Year	+81.14%	+36.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alnylam Pharmaceuticals Inc (DUL.SG)

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y

Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ...

Q1 2025 Alnylam Pharmaceuticals Inc Earnings Call

Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam: Q1 Earnings Snapshot

Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress

BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations

Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Receives CHMP Backing For RNAi Therapy Vutrisiran In Europe

Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline

Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy

Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline

Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires?

High Growth Tech Stocks In US With Potential For Expansion

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs

Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last?

Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy

Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires?

Performance Overview